[Skip to Content]
[Skip to Content Landing]
July 26, 1985


Author Affiliations

University of Colorado Health Sciences Center Denver
University of Utah Medical Center Salt Lake City

JAMA. 1985;254(4):506-507. doi:10.1001/jama.1985.03360040056018

To the Editor.—  The recent MEDICAL NEWS story1 on the growing applications for clinical use of luteinizing hormone-releasing hormone (LHRH) provides important updates on the use of this category of drug in the treatment of a number of conditions. With regard to the use of such analogues in the treatment of prostate carcinoma, Ms Ziporyn alluded to recent data2 that show a rise in serum luteinizing hormone (LH) and testosterone concentrations in patients who have been treated for a mean of 12.7 months with one LHRH analogue (ICI 118630), 250 μg daily. The authors of this article are quoted as stating that LHRH analogues should not be used "as a long-term treatment for carcinoma of the prostate."We have recently reported observations on 98 patients treated for a median of 72 weeks with an LHRH analogue, leuprolide (Lupron), given in 1-mg/day subcutaneous doses.3 Response rates and duration